In patients with neuromyelitis optica spectrum disorder (NMOSD), satralizumab continued to be well tolerated and to have a favourable safety profile when open-label extension period data were included in the analysis . The overall satralizumab treatment data were consistent with the double-blind periods.
Satralizumab is a humanised monoclonal antibody that binds to and blocks the IL-6 receptor and was shown to reduce NMOSD relapse risk in both the SAkuraSky (satralizumab in combination with baseline immunosuppressants), and the SAkuraStar (satralizumab monotherapy) phase 3 trials. The pooled double-blind population included 178 patients (satralizumab, n=104; placebo, n=74); 166 patients received satralizumab in the open-label extension period. The combined double-blind/extension period was defined as the overall satralizumab treatment period, in wh...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Eculizumab in NMOSD: the PREVENT study Next Article
Biomarkers predicting motor function in SMA »
Table of Contents: EAN 2020
Headache and Pain
Neuromyelitis Optica Spectrum Disorder
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.